## Covadonga M DÃ-az-Caneja

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1695353/publications.pdf

Version: 2024-02-01

99 papers 4,672 citations

30 h-index 63 g-index

111 all docs

111 docs citations

times ranked

111

7055 citing authors

#	Article	IF	Citations
1	Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism. Journal of Autism and Developmental Disorders, 2023, 53, 66-79.	2.7	2
2	Genetic and Structural Brain Correlates of Cognitive Subtypes Across Youth at Family Risk for Schizophrenia and Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2023, 62, 74-83.	0.5	2
3	Intracranial and subcortical volumes in adolescents with <scp>earlyâ€onset</scp> psychosis: A multisite <scp>megaâ€analysis</scp> from the <scp>ENIGMA</scp> consortium. Human Brain Mapping, 2022, 43, 373-384.	3.6	27
4	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33
5	Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia. Nature Communications, 2022, 13, 51.	12.8	16
6	Cortical thinning over two years after first-episode psychosis depends on age of onset. NPJ Schizophrenia, 2022, 8, 20.	3.6	3
7	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. Biological Psychiatry, 2022, 92, 299-313.	1.3	11
8	Longitudinal Allometry of Sulcal Morphology in Health and Schizophrenia. Journal of Neuroscience, 2022, 42, 3704-3715.	3.6	1
9	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	14.8	75
10	Leukocyte telomere length in patients with schizophrenia and related disorders: a meta-analysis of case-control studies. Molecular Psychiatry, 2022, 27, 2968-2975.	7.9	9
11	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophrenia Research, 2022, 243, 32-42.	2.0	15
12	Scalability of the Positive and Negative Syndrome Scale in firstâ€episode schizophrenia assessed by Rasch models. Acta Psychiatrica Scandinavica, 2022, 146, 21-35.	4.5	4
13	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. European Neuropsychopharmacology, 2022, 59, 45-55.	0.7	7
14	Assessment of School Anti-Bullying Interventions. JAMA Pediatrics, 2021, 175, 44.	6.2	69
15	Dissimilarity in Sulcal Width Patterns in the Cortex can be Used to Identify Patients With Schizophrenia With Extreme Deficits in Cognitive Performance. Schizophrenia Bulletin, 2021, 47, 552-561.	4.3	13
16	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. Schizophrenia Bulletin, 2021, 47, 444-455.	4.3	9
17	The interplay between functioning problems and symptoms in first episode of psychosis: An approach from network analysis. Journal of Psychiatric Research, 2021, 136, 265-273.	3.1	11
18	Efficacy of a Web-Enabled, School-Based, Preventative Intervention to Reduce Bullying and Improve Mental Health in Children and Adolescents: Study Protocol for a Cluster Randomized Controlled Trial. Frontiers in Pediatrics, 2021, 9, 628984.	1.9	6

#	Article	IF	Citations
19	How does neighbourhood socio-economic status affect the interrelationships between functioning dimensions in first episode of psychosis? A network analysis approach. Health and Place, 2021, 69, 102555.	3.3	3
20	The role of depression in the prediction of a "late―remission in first-episode psychosis: An analysis of the OPTiMiSE study. Schizophrenia Research, 2021, 231, 100-107.	2.0	4
21	Sex Differences in Lifespan Trajectories and Variability of Human Sulcal and Gyral Morphology. Cerebral Cortex, 2021, 31, 5107-5120.	2.9	9
22	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. European Neuropsychopharmacology, 2021, 47, 112-129.	0.7	20
23	Methodologic and Reporting Issues in Published Meta-analysis—Reply. JAMA Pediatrics, 2021, 175, 644.	6.2	O
24	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine, 2021, 36, 100909.	7.1	25
25	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry, 2021, 11, 423.	4.8	12
26	Association of Different Forms of Child Maltreatment With Peer Victimization in Mexican Children and Adolescents. Frontiers in Psychology, 2021, 12, 662121.	2.1	11
27	Premorbid Characteristics as Predictors of Early Onset Versus Adult Onset in Patients With a First Episode of Psychosis. Journal of Clinical Psychiatry, 2021, 82, .	2.2	6
28	First episode psychosis longitudinal cohort studies: The CIBERSAM FEP cohort. European Neuropsychopharmacology, 2021, 51, 132-133.	0.7	7
29	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. Journal of Clinical Medicine, 2021, 10, 73.	2.4	14
30	Psychosocial risk factors for suicidality in children and adolescents. European Child and Adolescent Psychiatry, 2020, 29, 759-776.	4.7	187
31	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. Schizophrenia Bulletin, 2020, 46, 432-441.	4.3	56
32	Sensory-to-Cognitive Systems Integration Is Associated With Clinical Severity in Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 422-433.	0.5	33
33	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. Schizophrenia Bulletin, 2020, 46, 517-529.	4.3	14
34	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a firstâ€episode psychosis cohort. Acta Psychiatrica Scandinavica, 2020, 141, 541-552.	4.5	6
35	T25. THE RELATIONSHIP BETWEEN AGE AT FIRST-EPISODE AND LONGITUDINAL CORTICAL CHANGES IN FIRST-EPISODE PSYCHOSIS: A TWO-YEAR LONGITUDINAL STUDY IN AN ADOLESCENT AND ADULT-ONSET COHORT. Schizophrenia Bulletin, 2020, 46, S240-S241.	4.3	O
36	S80. CHILDHOOD TRAUMA AND SOCIAL COGNITION IN DELUSIONAL PSYCHOSES. Schizophrenia Bulletin, 2020, 46, S64-S65.	4.3	0

#	Article	IF	CITATIONS
37	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. Schizophrenia Research, 2020, 223, 271-278.	2.0	9
38	T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S275-S275.	4.3	0
39	Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. Brain Sciences, 2020, 10, 572.	2.3	35
40	The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in young people with autism and schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2020, 13, 118-130.	0.3	0
41	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia – data from the OPTiMiSE trial. Psychiatry Research, 2020, 289, 112970.	3.3	11
42	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	4.2	135
43	The Relationship Between White Matter Microstructure and General Cognitive Ability in Patients With Schizophrenia and Healthy Participants in the ENIGMA Consortium. American Journal of Psychiatry, 2020, 177, 537-547.	7.2	49
44	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. Journal of Psychopharmacology, 2020, 34, 514-523.	4.0	12
45	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. Schizophrenia Research, 2020, 218, 292-294.	2.0	6
46	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. European Neuropsychopharmacology, 2020, 34, 76-86.	0.7	30
47	The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in young people with autism and schizophrenia. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 118-130.	1.8	5
48	Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. , 2020, , 303-316.		0
49	Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. Pediatrics, 2019, 144, .	2.1	40
50	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational Psychiatry, 2019, 9, 20.	4.8	52
51	10Kin1day: A Bottom-Up Neuroimaging Initiative. Frontiers in Neurology, 2019, 10, 425.	2.4	15
52	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry, the, 2019, 6, 427-436.	7.4	528
53	17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISODE PSYCHOSIS PATIENTS: THE OPTIMISE COHORT STUDY. Schizophrenia Bulletin, 2019, 45, S116-S117.	4.3	0
54	Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2019, 45, 742-751.	4.3	172

#	Article	IF	CITATIONS
55	Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders. Human Brain Mapping, 2019, 40, 1643-1653.	3.6	11
56	Cognition and functionality in delusional disorder. European Psychiatry, 2019, 55, 52-60.	0.2	14
57	Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE). Psychological Medicine, 2019, 49, 2600-2607.	4.5	10
58	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychological Medicine, 2019, 49, 1378-1391.	4.5	69
59	Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. Schizophrenia Bulletin, 2019, 45, 57-68.	4.3	18
60	Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. Schizophrenia Bulletin, 2019, 45, 69-79.	4.3	47
61	Temperament in child and adolescent offspring of patients with schizophrenia and bipolar disorder. European Child and Adolescent Psychiatry, 2018, 27, 1459-1471.	4.7	9
62	F19. TELOMERE SHORTENING IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTH FOLLOW-UP STUDY. Schizophrenia Bulletin, 2018, 44, S226-S226.	4.3	0
63	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. Psychological Medicine, 2018, 48, 2247-2256.	4.5	40
64	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophrenia Research, 2018, 193, 188-196.	2.0	50
65	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. Molecular Psychiatry, 2018, 23, 1261-1269.	7.9	522
66	Personality organization and its association with clinical and functional features in borderline personality disorder. Psychiatry Research, 2018, 262, 393-399.	3.3	16
67	Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis. Psychological Medicine, 2018, 48, 1592-1607.	4.5	27
68	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. JAMA Psychiatry, 2018, 75, 36.	11.0	235
69	Attenuated psychotic symptoms in children and adolescent offspring of patients with schizophrenia. Schizophrenia Research, 2018, 193, 354-358.	2.0	7
70	Adherence, insight and disability in paranoid schizophrenia. Psychiatry Research, 2018, 270, 274-280.	3.3	12
71	Preventive strategies for mental health. Lancet Psychiatry,the, 2018, 5, 591-604.	7.4	390
72	Impact of <i>NTRK2, DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. Journal of Psychopharmacology, 2018, 32, 702-710.	4.0	8

#	Article	IF	Citations
73	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	7.4	141
74	Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance. Psychological Medicine, 2017, 47, 193-197.	4.5	19
75	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. Schizophrenia Research, 2017, 189, 196-203.	2.0	13
76	Clinical, Cognitive, and Neuroimaging Evidence of a Neurodevelopmental Continuum in Offspring of Probands With Schizophrenia and Bipolar Disorder. Schizophrenia Bulletin, 2017, 43, 1208-1219.	4.3	38
77	A developmental approach to dimensional expression of psychopathology in child and adolescent offspring of parents with bipolar disorder. European Child and Adolescent Psychiatry, 2017, 26, 1165-1175.	4.7	10
78	The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies. NPJ Schizophrenia, 2017, 3, 40.	3.6	7
79	Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 2017, 20, 435-444.	2.1	95
80	The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis. Journal of Clinical Psychiatry, 2017, 78, e1233-e1241.	2.2	39
81	Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. Acta Psychiatrica Scandinavica, 2016, 133, 386-398.	4.5	103
82	Early interventions in risk groups for schizophrenia: what are we waiting for?. NPJ Schizophrenia, 2016, 2, 16003.	3.6	111
83	Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders. Psychiatry Research, 2016, 245, 427-435.	3.3	9
84	Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatrica Scandinavica, 2016, 133, 76-85.	4.5	44
85	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. International Journal of Neuropsychopharmacology, 2016, 19, pyv121.	2.1	29
86	Progressive brain changes in children and adolescents with early-onset psychosis: A meta-analysis of longitudinal MRI studies. Schizophrenia Research, 2016, 173, 132-139.	2.0	54
87	Gray Matter Volume Decrease Distinguishes Schizophrenia From Bipolar Offspring During Childhood and Adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 677-684.e2.	0.5	25
88	Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis. European Child and Adolescent Psychiatry, 2015, 24, 1447-1459.	4.7	19
89	Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophrenia, 2015, 1, 14005.	3.6	161
90	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229

#	Article	IF	Citations
91	Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 166-178.	1.8	9
92	A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. Schizophrenia Research, 2014, 158, 126-133.	2.0	33
93	Practitioner Review: Longâ€term pharmacological treatment of pediatric bipolar disorder. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2014, 55, 959-980.	5.2	20
94	Polypharmacy with antidepressants in children and adolescents. International Journal of Neuropsychopharmacology, 2014, 17, 1063-1082.	2.1	30
95	Empirical redefinition of delusional disorder and its phenomenology: the DELIREMP study. Comprehensive Psychiatry, 2013, 54, 243-255.	3.1	34
96	Prevalence of premorbid personality disorder and its clinical correlates in patients with delusional disorder. Psychiatry Research, 2013, 210, 986-993.	3.3	5
97	Clinical and Cognitive Correlates of Psychiatric Comorbidity in Delusional Disorder Outpatients. Australian and New Zealand Journal of Psychiatry, 2011, 45, 416-425.	2.3	30
98	Severe Bowel Ischemia Due to Clozapine With Complete Remission After Withdrawal. Journal of Clinical Psychopharmacology, 2010, 30, 463-465.	1.4	41
99	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. Schizophrenia Bulletin Open, 0, , .	1.7	2